These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 3875633)

  • 1. Elevated factor Xa activity in the blood of asymptomatic patients with congenital antithrombin deficiency.
    Bauer KA; Goodman TL; Kass BL; Rosenberg RD
    J Clin Invest; 1985 Aug; 76(2):826-36. PubMed ID: 3875633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Congenital antithrombin III deficiency: insights into the pathogenesis of the hypercoagulable state and its management using markers of hemostatic system activation.
    Bauer KA; Rosenberg RD
    Am J Med; 1989 Sep; 87(3B):39S-43S. PubMed ID: 2679069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection of factor Xa from neutralization by the heparin-antithrombin complex.
    Teitel JM; Rosenberg RD
    J Clin Invest; 1983 May; 71(5):1383-91. PubMed ID: 6222069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition.
    Demers C; Henderson P; Blajchman MA; Wells MJ; Mitchell L; Johnston M; Ofosu FA; Fernandez-Rachubinski F; Andrew M; Hirsh J
    Thromb Haemost; 1993 Mar; 69(3):231-5. PubMed ID: 8470046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of rat factors X and Xa: demonstration of factor Xa in rat plasma.
    Enjyoji K; Miyazaki K; Kato H
    J Biochem; 1991 Jun; 109(6):890-8. PubMed ID: 1718949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of antithrombin activity by thrombin-based and by factor Xa-based chromogenic substrate assays.
    Beeck H; Nagel D; Pindur G; Scharrer I; Preiss A; Seiler D; Hellstern P
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):127-35. PubMed ID: 10759005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of markers of activated coagulation in antithrombin III deficient subjects.
    Demers C; Ginsberg JS; Henderson P; Ofosu FA; Weitz JI; Blajchman MA
    Thromb Haemost; 1992 May; 67(5):542-4. PubMed ID: 1519214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Markers of procoagulant imbalance in patients with inherited thrombophilic syndromes.
    Mannucci PM; Tripodi A; Bottasso B; Baudo F; Finazzi G; De Stefano V; Palareti G; Manotti C; Mazzucconi MG; Castaman G
    Thromb Haemost; 1992 Feb; 67(2):200-2. PubMed ID: 1535736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a radioimmunoassay for quantitating prethrombin 2 in human plasma.
    Conway EM; Lau HK; Bauer KA; Rosenberg RD
    J Lab Clin Med; 1987 Nov; 110(5):567-75. PubMed ID: 3668358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of human factor Xa by various plasma protease inhibitors.
    Ellis V; Scully M; MacGregor I; Kakkar V
    Biochim Biophys Acta; 1982 Feb; 701(1):24-31. PubMed ID: 6173074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolation of antithrombin III from normal and alpha1-antitrypsin-deficient human plasma.
    Borsodi AD; Bradshaw RA
    Thromb Haemost; 1977 Aug; 38(2):475-85. PubMed ID: 304258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges with heparin-based anticoagulation during cardiopulmonary bypass in children: Impact of low antithrombin activity.
    Manlhiot C; Gruenwald CE; Holtby HM; Brandão LR; Chan AK; Van Arsdell GS; McCrindle BW
    J Thorac Cardiovasc Surg; 2016 Feb; 151(2):444-50. PubMed ID: 26553458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifactor Xa activity measured with amidolytic methods.
    Odegård OR; Lie M; Abildgaard U
    Haemostasis; 1976; 5(5):265-75. PubMed ID: 1017722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency.
    Herren T; Straub PW; Haeberli A
    Thromb Haemost; 1994 Jan; 71(1):49-53. PubMed ID: 8165646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of inhibition of the prothrombinase complex by a covalent antithrombin-heparin complex.
    Stevic I; Berry LR; Chan AK
    J Biochem; 2012 Aug; 152(2):139-48. PubMed ID: 22518847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of human activated Factor X by antithrombin III and alpha 1-proteinase inhibitor in human plasma.
    Gitel SN; Medina VM; Wessler S
    J Biol Chem; 1984 Jun; 259(11):6890-5. PubMed ID: 6202686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of anticoagulants used for blood collection on plasma prothrombin fragment F1 + 2 measurements.
    Bauer KA; Barzegar S; Rosenberg RD
    Thromb Res; 1991 Sep; 63(6):617-28. PubMed ID: 1780806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of heparin and heparinlike molecules in thrombosis and atherosclerosis.
    Rosenberg RD
    Fed Proc; 1985 Feb; 44(2):404-9. PubMed ID: 3155697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a novel, rapid assay for detection of heparin-binding defect antithrombin deficiencies: the heparin-antithrombin binding (HAB) ratio.
    Moore GW; de Jager N; Cutler JA
    Thromb Res; 2015 Jan; 135(1):161-6. PubMed ID: 25466846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.